H-001
氢氯噻嗪 溶液
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
InChI key
JZUFKLXOESDKRF-UHFFFAOYSA-N
InChI
1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)
SMILES string
NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl
grade
certified reference material
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
1.0 mg/mL in methanol
technique(s)
gas chromatography (GC): suitable, liquid chromatography (LC): suitable
application(s)
clinical testing
format
single component solution
storage temp.
−20°C
Quality Level
Gene Information
human ... SLC12A3(6559)
General description
氢氯噻嗪是一种保钙利尿剂，用于水肿和高血压的治疗。噻嗪类衍生物，氢氯噻嗪以商品名Microzide®和Aquazide H出售。该认证的加标溶液®适用于LC/MS或GC/MS应用，例如临床毒理学和法医分析。
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Microzide is a registered trademark of Watson Laboratories, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
target_organs
Eyes,Central nervous system
存储类别
3 - Flammable liquids
wgk
WGK 2
flash_point_f
49.5 °F - closed cup
flash_point_c
9.7 °C - closed cup
法规信息
危险化学品
此项目有
Michael A Weber et al.
Lancet (London, England), 381(9866), 537-545 (2012-12-12)
In previous clinical trials in high-risk hypertensive patients, paradoxically higher cardiovascular event rates have been reported in patients of normal weight compared with obese individuals. As a prespecified analysis of the Avoiding Cardiovascular Events through Combination Therapy in Patients Living
Alexander V Murray et al.
Journal of clinical hypertension (Greenwich, Conn.), 14(12), 821-827 (2012-12-05)
Combination antihypertensive therapies are recommended to attain blood pressure (BP) targets especially in high-risk patients in whom rapid and pronounced BP control is essential. This 28- to 54-week, open-label, multicenter study evaluated the safety and efficacy of a triple combination
Sympathetic activation and endothelial dysfunction as therapeutic targets in obesity-related hypertension.
Brent Egan et al.
Journal of hypertension, 31(2), 259-260 (2013-01-11)
Successful rapid desensitization to hydrochlorothiazide.
Jamma Li et al.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 110(4), 307-308 (2013-03-29)
M Al Qahtani et al.
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 24(2), 281-285 (2013-03-30)
Hyponatremia is the most frequently encountered electrolyte abnormality among hospitalized patients and thiazide users. In this large single-center retrospective study, we aim to determine the prevalence and risk factors of hyponatremia among patients at the King Abdulaziz Medical City (KAMC)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持